Author

Melinda M. Mulvihill

GenentechORCID 0000-0002-0057-1204Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

Anna ShemorryiD· 1 shared Carrie R. GraveeliD· 1 shared Curt J. EssenburgiD· 1 shared Danilo MaddaloiD· 1 shared Elisia VillemureiD· 1 shared Elizabeth A. Tovar· 1 shared Elizabeth Levy· 1 shared Emily WolfrumiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anna ShemorryORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyCell chemical biologyPeer-reviewedMay 1, 2025

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

Anna Shemorry, Willem den Besten, Melinda M. Mulvihill…·Ingrid E. Wertz

This study evaluates bifunctional ER degraders with different ubiquitin ligase ligands, finding that pan-IAP antagonists enhance ER degradation and induce TNF-dependent cell death more effectively than existing therapies.

1 citation

humanproteomics

𝕏 PostBluesky